Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

TNX-4800Positive

AI Analysis

Summary

Tonix Pharmaceuticals announced positive minutes from a Type C FDA meeting to discuss an adaptive Phase 2 field study of TNX-4800, a human anti-OspA monoclonal antibody for Lyme disease prevention.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Positive minutes from Type C FDA meeting regarding adaptive Phase 2 field study

Importance:6/10

Sentiment:

0.70

FDA MeetingType C MeetingLyme DiseaseMonoclonal AntibodyAdaptive Study

Related Companies

$TNXP

Read the original article

Published by yahoo_finance on August 3, 2026 11:00 AM

Read Original